Get the Stockscreener App
34.73
1.19%
-0.42
After Hours:
34.62
-0.11
-0.32%
Vericel Corp stock is traded at $34.73, with a volume of 383.20K.
It is down -1.19% in the last 24 hours and up +1.05% over the past month.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
See More
Previous Close:
$35.15
Open:
$35.24
24h Volume:
383.20K
Relative Volume:
0.59
Market Cap:
$1.77B
Revenue:
$276.26M
Net Income/Loss:
$16.52M
P/E Ratio:
112.83
EPS:
0.3078
Net Cash Flow:
$24.75M
1W Performance:
+5.15%
1M Performance:
+1.05%
6M Performance:
-12.25%
1Y Performance:
-16.07%
1-Day Range:
$34.67
$35.47
1-Week Range:
$33.03
$36.35
52-Week Range:
$28.95
$45.97
Vericel Corp Stock (VCEL) Company Profile
Name
Vericel Corp
Sector
Industry
Phone
(734) 930-5555
Address
64 SIDNEY ST., CAMBRIDGE, MA
Compare VCEL vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VCEL
Vericel Corp
|
34.73 | 1.80B | 276.26M | 16.52M | 24.75M | 0.3078 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vericel Corp Stock (VCEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-09-24 | Initiated | Canaccord Genuity | Buy |
| Jun-20-24 | Initiated | TD Cowen | Buy |
| Jan-25-24 | Upgrade | Truist | Hold → Buy |
| Aug-08-23 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-10-22 | Downgrade | BTIG Research | Buy → Neutral |
| Nov-09-22 | Downgrade | Truist | Buy → Hold |
| Oct-14-22 | Resumed | Stephens | Overweight |
| Jan-11-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-18-20 | Initiated | Stephens | Overweight |
| Sep-17-20 | Initiated | Truist | Buy |
| Oct-09-19 | Initiated | H.C. Wainwright | Buy |
| Feb-28-19 | Downgrade | Needham | Buy → Hold |
| Aug-08-18 | Reiterated | Needham | Buy |
| Jul-16-18 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Apr-04-18 | Initiated | Leerink Partners | Outperform |
| Mar-06-18 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-06-18 | Reiterated | Needham | Buy |
| Mar-05-18 | Reiterated | BTIG Research | Buy |
| Jun-21-17 | Initiated | BTIG Research | Buy |
| Mar-13-17 | Reiterated | Needham | Buy |
| Dec-22-16 | Initiated | Piper Jaffray | Overweight |
| Nov-09-16 | Reiterated | Needham | Buy |
| Apr-05-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| Mar-11-16 | Upgrade | Needham | Hold → Buy |
View All
Vericel Corp Stock (VCEL) Latest News
Q1 2026 Vericel Corp Earnings Call Transcript - GuruFocus
Q3 2025 Vericel Corp Earnings Call Transcript - GuruFocus
Vericel (VCEL) amends bylaws to reflect new Burlington, MA global headquarters - Stock Titan
Vericel Corporation $VCEL Stock Position Reduced by Truist Financial Corp - MarketBeat
Vericel (VCEL) director McLaughlin exercises options and sells 7,000 shares - Stock Titan
VCEL Stock Price, Quote & Chart | VERICEL CORP (NASDAQ:VCEL) - ChartMill
Vericel CorporationCommon Stock (NQ: VCEL - FinancialContent
Vericel director Paul Wotton sells $327,425 in company stock By Investing.com - Investing.com Australia
Insider Sell: Paul Wotton Sells 10,000 Shares of Vericel Corp (V - GuruFocus
Vericel director Paul Wotton sells $327,425 in company stock - Investing.com
Director Paul K. Wotton sells 10,000 Vericel (VCEL) shares around $33 - Stock Titan
Issuer (NASDAQ: VCEL) notifies sale of 7,000 common shares - Stock Titan
Vericel (VCEL) Eps Diluted (TTM) - Zacks Investment Research
TradingKey - tradingkey.com
[144] Vericel Corp SEC Filing - Stock Titan
What is HC Wainwright's Estimate for Vericel Q4 Earnings? - MarketBeat
Analysts Have Made A Financial Statement On Vericel Corporation's (NASDAQ:VCEL) First-Quarter Report - Yahoo Finance
Vericel Corporation (NASDAQ:VCEL) Q1 2026 Earnings Call Transcript - Insider Monkey
Vericel Corp (NASDAQ:VCEL): A Prime Example of Affordable Growth - ChartMill
Vericel Q1 Earnings Call Highlights - Yahoo Finance
Insider Sell: Mara Joseph Anthony Jr Sells 5,000 Shares of Veric - GuruFocus
Analysts Offer Insights on Healthcare Companies: Vericel (VCEL) and BridgeBio Pharma (BBIO) - The Globe and Mail
Vericel (VCEL) CFO 10b5-1 sale leaves 21,009 shares held - Stock Titan
Vericel (NASDAQ: VCEL) accounting chief sells 4,855 shares - Stock Titan
VCEL Maintains Buy Rating by HC Wainwright & Co. -- Price Target Raised to $64.00 - GuruFocus
Vericel Q1 2026 slides: 30% revenue growth drives guidance raise By Investing.com - Investing.com Australia
MSN Money - MSN
VCEL PE Ratio & Valuation, Is VCEL Overvalued - Intellectia AI
Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance - Ortho Spine News
Vericel Q1 2026 slides: 30% revenue growth drives guidance raise - Investing.com
Earnings call transcript: Vericel’s Q1 2026 beats forecasts, stock surges - Investing.com
Jonathan Siegal files Form 144 — VCEL (NASDAQ: VCEL) sells 3,433 shares - Stock Titan
Vericel Corporation (VCEL) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Vericel Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Vericel Corp 1Q 2026: Revenue $68.43M, EPS ($0.12) — 10-Q Summary - TradingView
BARDA burns contract backs NexoBrid growth at Vericel (VCEL) - Stock Titan
Vericel Corp (NASDAQ:VCEL) Smashes Q1 Estimates, Raises Full-Year Outlook as MACI and Burn Care Surge - ChartMill
VERICEL ($VCEL) Releases Q1 2026 Earnings - Quiver Quantitative
Vericel Reports Q1 2026: Revenue Up 30% to $68.4M, Adjusted EBITDA $9.6M - TradingView
Vericel (NASDAQ: VCEL) lifts 2026 outlook after 30% Q1 revenue gain - Stock Titan
Vericel Corporation Reports 30% Revenue Growth to $68.4 Million in Q1 2026, Raises Full-Year Guidance to $326-$336 Million - Quiver Quantitative
Burn care sales surge 91% as Vericel lifts 2026 revenue target - Stock Titan
VCEL (NASDAQ: VCEL) Form 144 lists 3,433 shares valued $130,454; vesting noted - Stock Titan
Vericel faces earnings test as Q1 loss looms after FDA approval - Investing.com Australia
Vericel faces earnings test as Q1 loss looms after FDA approval By Investing.com - Investing.com South Africa
Global Stem Cell Therapy Market Set to Flourish at a CAGR of ~11% by 2034 Owing to the Technological Advancements and Favorable Regulations | DelveInsight - GlobeNewswire Inc.
Vericel Corp (NASDAQ:VCEL) Presents a Compelling Growth and Technical Setup Opportunity - ChartMill
Vericel Corp Stock (VCEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):